Contents

Search


vascular endothelial growth factor (VEGF) inhibitor

Indications: - VEGF inhibitors improve vision in diabetic macular edema [1] - aflibercept may be most effective for worst baseline vision - age-related macular degeneration [4] - bevacizumab is used as an antineoplastic agent for metastatic colorectal cancer, lung cancer, ovarian cancer, breast cancer, malignant brain tumor, advanced cervical cancer, metastatic renal cell carcinoma Dosage: - intravitreous administration Adverse effects: - thrombotic microangiopathy - hypertension [3] Mechanism of action: - inhibits vascular endothelial growth factor (VEGF)

Related

vascular endothelial growth factor family protein (VEGF family) vascular endothelial growth factor [VEGF] receptor

Specific

aflibercept (Eylea) bevacizumab (Avastin, Altuzan) brolucizumab; brolucizumab-dbll (Beovu) ranibizumab (Lucentis, Byooviz)

General

enzyme inhibitor pharmaceutical angiogenesis inhibitor (angiostatic agent)

References

  1. The Diabetic Retinopathy Clinical Research Network. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. N Engl J Med. 2015 Feb 18. PMID: 25692915 http://www.nejm.org/doi/full/10.1056/NEJMoa1414264 - Martin DF, Maguire MG. Treatment Choice for Diabetic Macular Edema. N Engl J Med. 2015 Feb 18. [Epub ahead of print] PMID: 25692914 http://www.nejm.org/doi/full/10.1056/NEJMe1500351
  2. Usui J, Glezerman IG, Salvatore SP Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature. Hum Pathol. 2014 Sep;45(9):1918-27. Review. PMID: 25087655
  3. Robinson ES, Khankin EV, Karumanchi SA, Humphreys BD. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. Semin Nephrol. 2010 Nov;30(6):591-601. Review. PMID: 21146124 Free PMC Article
  4. Finger RP, Puth MT, Schmid M et al Lifetime Outcomes of Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. 2020;138(12):1234-1240. PMID: 33057589 PMCID: PMC7563682 https://jamanetwork.com/journals/jamaophthalmology/fullarticle/10.1001/jamaophthalmol.2020.3989